Improving Muscle Function in Nutritionally at Risk, Elderly Patients
- Conditions
- ICU-acquired WeaknessMuscle Weakness
- Interventions
- Dietary Supplement: Nutritional SupplementDietary Supplement: HMB protein supplement (3g)
- Registration Number
- NCT03071354
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
The investigators propose to conduct a randomized, control trial of β-hydroxy-β-methylbutyrate (HMB) supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by ICU-specific nutritional risk scores. Patients will receive either 3g of HMB daily, or control, daily until day 28 following randomization (even if discharged).The investigators will measure functional outcomes using standard, validated measures prior and after discharge.
- Detailed Description
The investigators propose to conduct a randomized, control trial of HMB supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by ICU-specific nutritional risk scores. Patients will receive either 3g of HMB daily, or control, daily until day 28 following randomization (even if discharged).the investigators will measure functional outcomes using standard, validated measures prior and after discharge.
The investigators hypothesize that this inexpensive nutrient, HMB, along with our supportive measures, reduces muscle loss, improves physical muscle function, and improves quality of life in the longer term following critical illness.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Patients age ≥65 years.
- Acute respiratory failure (ARF, defined by expected mechanical ventilation for > 72 hours from the point of screening)
- Elevated nutritional risk (NUTRIC score>5 - see below).
- Over 72 hours from ICU admission.
- Not expected to survive another 48 hours
- Lack of commitment to full, aggressive care
- Patients who have an absolute contraindication to EN (obstruction, perforation, high output fistula),
- Pregnant women
- Prisoners
- Known allergy to study nutrients
- Unable to walk prior to current illness.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Group Nutritional Supplement Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study. In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards. HMB Protein Supplementation Group HMB protein supplement (3g) Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study. In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards.
- Primary Outcome Measures
Name Time Method 6 minute walk distance At 42 days follow up Maximum distance walked by subject in 6 minutes on level ground
- Secondary Outcome Measures
Name Time Method Body Composition-Quadriceps layer muscle thickness (QLMT) At 42 days follow up Thigh ultrasound for quadriceps muscle thickness
Body Composition-Calf circumference At 42 days follow up Measurement of the calf circumference
Timed Get Up and Go test At 42 days follow up Time for subject to go from sitting to standing unaided
Hand-grip strength (HGS) At 42 days follow up Measurement of force of isometric grip strength using hand-held dynamometer
Trial Locations
- Locations (1)
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States